Tribunal rules on corporate guarantees and clinical trial services, adjusting to High Court precedent

The Tribunal rejected the assessee's argument that corporate guarantees are not international transactions but disagreed with the 3% adjustment, directing a 0.5% arm's length consideration based on a jurisdictional High Court precedent. For clinical trial services, the Tribunal upheld the assessee's plea to use segmental margins for comparison, remitting the issue for reassessment at the assessment stage. The appeal was partly allowed, with adjustments made for corporate guarantees and a reconsideration of clinical trial services using segmental results.

---

---

Issues Involved:
1. Transfer Pricing Adjustment for Corporate Guarantees.
2. Transfer Pricing Adjustment for Clinical Trial Services.

Detailed Analysis:

1. Transfer Pricing Adjustment for Corporate Guarantees

Background:
The assessee appealed against an order confirming a transfer pricing adjustment of Rs. 1,19,82,672/- related to corporate guarantees provided to its overseas subsidiaries. The appellant argued that the corporate guarantees should not be considered international transactions under Transfer Pricing regulations and that the 1.75% commission already charged should suffice.

Arguments:
- Assessee's Argument: The assessee contended that the issue was previously decided in their favor for earlier assessment years, where it was held that corporate guarantees do not constitute international transactions under section 92B of the Income Tax Act. They also argued that the non-jurisdictional High Court's decision in Redington India Ltd should not bind the Tribunal.
- Department's Argument: The Department argued that higher judicial forums' decisions must be followed, and the 3% adjustment should be upheld.

Tribunal's Observations:
- The Tribunal emphasized the principle of judicial hierarchy, quoting the Supreme Court's stance that lower courts must accept higher courts' decisions.
- The Tribunal noted that while non-jurisdictional High Court decisions are not binding, they carry persuasive value and should be followed unless there are strong reasons not to.
- The Tribunal concluded that the issuance of corporate guarantees does constitute an international transaction, aligning with the Madras High Court's decision in Redington India Ltd.

Decision:
- The Tribunal rejected the assessee's plea that corporate guarantees are not international transactions.
- However, it disagreed with the 3% arm's length price adjustment, citing the jurisdictional High Court's precedent in CIT Vs Everest Kento Cylinders Ltd, which upheld a 0.5% adjustment for corporate guarantees.
- The Tribunal directed the Assessing Officer to adopt 0.5% as the arm's length consideration for the corporate guarantees.

2. Transfer Pricing Adjustment for Clinical Trial Services

Background:
The assessee contested a transfer pricing adjustment of Rs. 3,43,42,062/- related to clinical trial services provided to its Associated Enterprises (AEs). The dispute centered on whether entity-level margins or segmental margins should be used for comparison.

Arguments:
- Assessee's Argument: The assessee argued that segmental margins should be used for comparison, as they better reflect the transactions with AEs.
- Department's Argument: The Department maintained that entity-level margins should be used, as the functions and activities of AEs and non-AEs are not comparable.

Tribunal's Observations:
- The Tribunal noted that when segmental results are available and undisputed, they should be preferred over entity-level results.
- It was observed that in a subsequent assessment year, the TPO accepted the segmental approach, indicating inconsistency in the Department's stance.

Decision:
- The Tribunal upheld the assessee's plea in principle, directing the Assessing Officer to reconsider the matter using segmental results.
- The issue was remitted back to the assessment stage for reevaluation in light of the Tribunal's observations.

Conclusion:
The appeal was partly allowed. The Tribunal directed a 0.5% arm's length adjustment for corporate guarantees and remitted the issue of clinical trial services for reconsideration using segmental results.

---